Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
OrthoPediatrics Corp. develops and commercializes medical devices for pediatric orthopedics, with products used in trauma and deformity, scoliosis, sports medicine and related procedures. Company news commonly covers quarterly financial results, revenue by product category, domestic and international sales trends, cash-flow metrics and updates to financial guidance.
Recurring product and market updates include specialty bracing, spine and deformity correction systems, implants, instruments and enabling technologies for pediatric care. Announcements also include investor conference participation and portfolio additions such as hospital-based traction systems and other products aimed at children with orthopedic conditions.
OrthoPediatrics (Nasdaq: KIDS) reported Q1 2026 revenue of $59.4M, up 13% year-over-year, with U.S. revenue of $45.3M (76%) and international revenue of $14.1M (24%).
Adjusted EBITDA was $2.2M, free cash flow usage improved 40% to $5.0M, and full-year 2026 revenue guidance was raised to $263.0M–$267.0M.
OrthoPediatrics (Nasdaq: KIDS) expanded its OrthoPediatrics Specialty Bracing portfolio by launching the TRAXIO Complete - Weight System, a Halo Gravity Traction device developed with Synetik Group to provide controlled, weight-based axial traction for gradual spinal realignment in pediatric patients in hospital settings.
TRAXIO is a mechanical, non-active weight-and-pulley system intended for use with a separately cleared cranial halo ring and pin system to support halo gravity traction therapy.
OrthoPediatrics (Nasdaq: KIDS) will report first quarter 2026 financial results on Thursday, April 30, 2026 after market close and will host a conference call the same day at 4:30 p.m. ET.
According to the company, a live and archived webcast will be available on the Investors page at www.orthopediatrics.com, with replay access for at least 90 days.
OrthoPediatrics (Nasdaq: KIDS) announced that CEO Dave Bailey and COO/CFO Fred Hite will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 9:30 am ET.
An audio webcast will be available on the company’s investor relations website, with a replay posted after the event.
OrthoPediatrics (Nasdaq: KIDS) will participate in two investor conferences in March 2026 with fireside chats on March 3 and March 10. An audio webcast will be available on the company's investor relations site, with a replay available for 90 days after each event.
OrthoPediatrics (Nasdaq: KIDS) reported record full year 2025 revenue of $236.3 million, up 15% year-over-year, and fourth quarter 2025 revenue of $61.6 million, up 17% year-over-year. The company achieved full year adjusted EBITDA of $14.8 million and generated positive free cash flow of $9.8 million in Q4, its first quarter of positive free cash flow. Management reiterated 2026 guidance: revenue of $262.0–$266.0 million (+11% to +13%), adjusted EBITDA of $25 million, and breakeven free cash flow.
Q4 gross margin improved to 73.2%, net loss narrowed to $10.1 million for the quarter and full year net loss was $39.6 million. Cash and short-term investments totaled $62.9 million at year-end.
OrthoPediatrics (Nasdaq: KIDS) will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. The company will host a conference call the same day at 4:30 p.m. ET to discuss the results.
Investors can access a live and archived webcast on the company's Investors page in the Events & Presentations section; the replay will be available for at least 90 days.
OrthoPediatrics (Nasdaq: KIDS) announced that partner iotaMotion received FDA 510(k) clearance to expand use of the iotaSOFT® cochlear implant insertion system to patients four years and older on Feb. 3, 2026. The clearance extends access to robotic-assisted cochlear implantation for school-aged children.
Cincinnati Children’s Hospital is the first dedicated pediatric center to adopt iotaSOFT, joining over 35 U.S. cochlear implant centers and many neurotology fellowship programs that have adopted the technology. OrthoPediatrics positions this as strategic growth for its Enabling Technologies division to expand beyond orthopedics while remaining capital-light.
OrthoPediatrics (Nasdaq: KIDS) reported preliminary unaudited full year 2025 net revenue of $236.1M, up 15% vs. 2024, with domestic revenue of $186.2M (+16%) and international revenue of $49.9M (+15%). Q4 2025 preliminary revenue was $61.3M (+16% YoY), with domestic Q4 at $48.4M (+13%) and international Q4 at $12.9M (+32%). The company generated approximately $6.0–$7.0M of Q4 free cash flow and reduced full-year free cash flow usage by over 50% vs. 2024. The company received EUMDR certification for Response Spine products and related trauma and deformity devices. For 2026, OrthoPediatrics guides revenue of $262M–$266M (11%–13% growth), expects ~$10M annual set deployment and projects $25M Adjusted EBITDA.
OrthoPediatrics (Nasdaq: KIDS) announced on November 13, 2025 an expansion of its OrthoPediatrics Specialty Bracing (OPSB) portfolio with two new product launches: the PediHip™ Rigid Brace and PediHip™ Modular Abduction System.
The PediHip products, developed with pediatric hip experts, are intended to treat developmental dysplasia of the hip (DDH) and provide post-operative stabilization for children age three years and younger. OrthoPediatrics now offers 31 systems within its OPSB division and positions the PediHip portfolio alongside its Trauma & Deformity products to address the pediatric hip care continuum.